# Metcela

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/metcela

- Industry: Biotechnology
- Headquarters: Tsuruoka, Japan
- Website: www.metcela.com/
- Total disclosed funding: $28M
- Latest round: Series C (Jun 28, 2022)
- Investors on record: 16

## About

Metcela Inc., based in Japan, is focused on developing innovative regenerative medicine therapies, particularly targeting pediatric congenital heart disease through their leading product, JRM-001. The company aims to enhance patient care and healing through advanced cellular treatments.Founded in 2016 and headquartered in Tsuruoka, Japan, Metcela Inc. develops cell therapies for pediatric heart conditions. The company has participated in 7 funding deals, with the latest being a Series C round in June 2022 where they raised JPY 1.27 billion, led by CEJ Capital and CYBERDYNE, Inc., alongside other investors. The founders, Kenichi Nogami and Takahiro Iwamiya, have aimed to carve a niche in regenerative medicine, enhancing the company’s operational focus on cellular innovation. With a current valuation of JPY 6,911.31 million, the firm continues to evolve its business strategy in the healthcare sector.Metcela Inc. specializes in regenerative medicine, focusing on their flagship product, JRM-001, designed to treat pediatric congenital heart disease. This therapy targets the cellular mechanisms underlying these conditions, enhancing patient quality of life by promoting cellular healing. Metcela collaborates with healthcare providers and medical facilities throughout Japan to ensure access to their advanced therapies, prioritizing impactful patient outcomes.Metcela Inc. generates revenue primarily through the commercialization of JRM-001, engaging in B2B transactions with healthcare institutions and facilities. Their revenue model includes direct sales of the therapy to hospitals and collaborations with research institutions for clinical trials. Successful adoption of JRM-001 is central to their revenue strategy, as they establish a network of healthcare providers to incorporate their therapies into clinical practice.In June 2022, Metcela Inc. raised JPY 1.27 billion in Series C funding, co-led by CYBERDYNE, Inc. and CEJ Capital, with participation from Japan Lifeline and Reazon Holdings, along with returning investor Sony Ventures. The company plans to utilize these funds to further develop a global ecosystem of self-regenerative medicine products. Metcela aims to expand its market reach by introducing new therapies and targeting additional geographic regions, enhancing its capabilities in regenerative healthcare.

## Funding rounds

- Series C, Jun 28, 2022, $9.4M — Cyberdyne, Inc., Sony Innovation Fund, CEJ Capital, Japan Lifeline Co.,Ltd., Reazon Holdings
- Series C, Apr 4, 2022, $0.4M — Osaka University Venture Capital, TOHOKU University Venture Partners
- Series B, Mar 31, 2021, $0.9M — Eight Roads Ventures, F-Prime Capital
- Series B, Jan 4, 2021, $8.7M — University of Tokyo Edge Capital Partners, Dai-ichi Life Asset Management Co. Ltd, KSP, Spurcle, Alfresa Corporation
- Series B, Apr 28, 2020, $4M — Sony Innovation Fund, Joyo Industrial Research, Japan Lifeline Co.,Ltd.
- Series A, Aug 30, 2018, $4.7M — Eight Roads Ventures, F-Prime Capital, Dai-ichi Life Asset Management Co. Ltd, KSP, Beyond Next Ventures, Sony Innovation Fund, Japan Lifeline Co.,Ltd.

## Investors

- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series A, Series B
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A, Series B
- Dai-ichi Life Asset Management Co. Ltd — Series A, Series B
- KSP (https://capitalatlas.ai/funds/ksp) — Series A, Series B
- Beyond Next Ventures (https://capitalatlas.ai/funds/beyond-next-ventures) — Series A
- Sony Innovation Fund (https://capitalatlas.ai/funds/sony-innovation-fund) — Series A, Series B, Series C
- Japan Lifeline Co.,Ltd. — Series A, Series B, Series C
- Joyo Industrial Research (https://capitalatlas.ai/funds/joyo-industrial-research) — Series B
- University of Tokyo Edge Capital Partners (https://capitalatlas.ai/funds/university-of-tokyo-edge-capital-partners) — Series B
- Spurcle (https://capitalatlas.ai/funds/spurcle) — Series B
- Alfresa Corporation — Series B
- Osaka University Venture Capital (https://capitalatlas.ai/funds/osaka-university-venture-capital) — Series C
- TOHOKU University Venture Partners (https://capitalatlas.ai/funds/tohoku-university-venture-partners) — Series C
- Cyberdyne, Inc. — Series C
- CEJ Capital (https://capitalatlas.ai/funds/cej-capital) — Series C
- Reazon Holdings — Series C